Remove 2012 Remove Competition Remove Side effects
article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4

Medicine 116
article thumbnail

Briumvi may struggle to make headway in crowded multiple sclerosis market

Pharmaceutical Technology

As for Briumvi’s side effects, around 45% of patients experienced infections of the upper respiratory tract, which was 4% higher in comparison to Aubagio. As for Briumvi’s side effects, around 45% of patients experienced infections of the upper respiratory tract, which was 4% higher in comparison to Aubagio.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Beating the Big C

Pharmaceutical Technology

” Supply and revenue Cancer drugs can plug revenue gaps created by loss of patents in other areas, as Pfizer hopes to do when competition for its cholesterol fighter Lipitor opens up in two years’ time. Until those side effects have been dealt with, we can’t really proclaim victory.”

article thumbnail

Pharmaceutical Patents: A Challenge for Malaysia

Contrarian Sales Techniques

There was an article that examine the market for generic medicines in the Malaysia, following the introduction of the first generic patent in 2010 and the introduction of generic patent law in 2012. I understand that in developing countries, citizens can usually trust that the medicines on pharmacy shelves are safe, authentic, and effective.